Xarelto study backs new clot-fighting indication; Roche extends Illumina bid, again;

 @FiercePharma: Another casualty of pharma's sales cuts: Spending on drug samples drops 25%. Rep visits fell by 35%, incidentally. More | Follow @FiercePharma

> A study comparing Bayer and Johnson & Johnson's clot-fighting drug Xarelto to combo therapy with warfarin and heparin added support to a potential new indication in patients with blood clots in their lungs. Report

> Roche once again extended its offer for the gene-sequencing firm Illumina, at the same per-share price of $44.50, a total of $5.7 billion cash. Report

> A Brazilian judge annulled Abbott Laboratories' patent on the AIDS drug Kaletra, opening the field for generics maker Critalia to produce a copycat version. Report

> The Canadian government opened up its emergency stocks of some drugs to help alleviate shortages. Report

> Teva Pharmaceutical Industries plans to sell senior notes denominated in euros and Swiss francs, aiming to raise money to pay off maturing debt. Report

> A federal judge set the dates for two bellwether trials in the litigation over Pfizer's Chantix, in which families allege the stop-smoking medicine triggered patients' suicides and other patients sue over their psychiatric problems. Report

> Amylin Pharmaceuticals and Eli Lilly said their diabetes drug Byetta won European approval for use in combination with basal insulin. Report

Biotech News

 @FierceBiotech: Sequencing DNA with a thumb drive faces skepticism. News | Follow @FierceBiotech

 @JohnCFierce: Merck: I paid $41 billion for Schering-Plough and all I got was this added risk of bleeding. Story | Follow @JohnCFierce

 @RyanMFierce: Sounds doable. Duke U. is looking for a "virtual lock box," software to ensure integrity of research data. Article | Follow @RyanMFierce

@FierceMedDev: Medtronic's Nerve-Searing Therapy Treats Hypertension for Years. Story via @BloombergNews | Follow @FierceMedDev

> Bleeding risk clouds Merck's hopes for vorapaxar franchise. Article

> FDA accusations of "corrupt" lab practices push Cetero into bankruptcy. News

> Private equity player pumping $50M into cancer drug startup. Story

> Amgen CEO's retirement pay could register at $49M. Item

Biotech IT News

> Duke seeks IT fixes to research tampering after Potti probe. More

> NIH cancer informatics drive goes under the knife. Story

> Microsoft co-founder pumping $300M into open research of the brain. News

> BioClinica and NextDocs partner on eClinical software. Item

Medical Device News

> Medtronic touts positive results with Symplicity for hypertension. News

> Yale-developed MRI penetrates bones and tissues. Item

> FDA could revoke Stryker Wingspan brain stent approval. More

> Study: Riata wires have additional risky defects. Report

> BiO2 snaps up $13.7M in Series B. News

And finally... A picture is worth more than doctor's verbal advice: When shown images of calcification in their heart arteries, patients were more likely to stick with statin therapy. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.